التفاصيل البيبلوغرافية
| العنوان: |
Real-World Management and Outcomes of Crizotinib-Treated ROS1-Rearranged NSCLC: A Retrospective Canadian Cohort. |
| المؤلفون: |
Gibson, Amanda J. W., Box, Adrian, Cheung, Winson Y., Dean, Michelle L., Elegbede, Anifat A., Hao, Desiree, Pabani, Aliyah, Sangha, Randeep, Bebb, Dafydd Gwyn |
| المصدر: |
Current Oncology; Mar2022, Vol. 29 Issue 3, p1967-1982, 16p, 1 Diagram, 4 Charts, 2 Graphs |
| مصطلحات موضوعية: |
LUNG cancer, DRUG tolerance, IMMUNE checkpoint inhibitors, RETROSPECTIVE studies, METASTASIS, PIPERIDINE, CANCER patients, PROTEIN-tyrosine kinases, GENE rearrangement, PEMETREXED, LONGITUDINAL method, IMMUNOTHERAPY |
| مصطلحات جغرافية: |
CANADA |
| مستخلص: |
The use, safety and effectiveness of crizotinib as part of the management of ROS1-rearranged NSCLC patients in a real-world Canadian clinical cohort was the focus of this retrospective review. Twenty-one ROS1-rearranged patients with advanced/metastatic disease receiving crizotinib between 2014–2020 were identified; crizotinib demonstrated tolerability and effectiveness in this population where outcomes were similar to those described in other crizotinib-treated real-world cohorts, but lower than those of the PROFILE 1001 clinical trial population. Systemic anti-cancer therapy prior to crizotinib initiation occurred in half of the study cohort, with platin-pemetrexed and immune checkpoint inhibitors being most common. Platin-pemetrexed showed good effectiveness in this cohort, but despite high prevalence of upregulated PD-L1 expression, immune checkpoint inhibitors showed poor effectiveness in his cohort. Among all systemic therapies received, crizotinib showed the most effective disease control, although longer intervals between diagnosis and crizotinib initiation were more common among those showing a lack of clinical response to crizotinib, and patients with brain metastases at the time of crizotinib initiation also showed increased diagnosis to crizotinib initiation intervals and decreased clinical response to crizotinib. This study reveals crizotinib has clinical benefit, but timely identification of ROS1-rearrangements and initiation targeted therapies appears important to maximize outcome in this population. [ABSTRACT FROM AUTHOR] |
|
Copyright of Current Oncology is the property of MDPI and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.) |
| قاعدة البيانات: |
Complementary Index |
Full Text Finder